(Q41646436)

6 October 2017

1 reference

title

A closer look at vancomycin, teicoplanin, and antimicrobial resistance (English)

1 reference

6 October 2017

1 reference

Zeckel ML

1

1 reference

6 October 2017

1 October 1997

1 reference

6 October 2017

Journal of Chemotherapy

1 reference

6 October 2017

9

1 reference

6 October 2017

5

1 reference

6 October 2017

311-31; discussion 332-5

1 reference

World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus.

6 October 2017

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

In vitro activities of vancomycin and teicoplanin against coagulase-negative staphylococci isolated from neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

In-vitro teicoplanin-resistance in coagulase-negative staphylococci from patients with endocarditis and from a cardiac surgery unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Protein binding of vancomycin in a patient with immunoglobulin A myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Protein binding and serum bactericidal activities of vancomycin and teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Bactericidal activity of antibiotics alone and in combination against Enterococcus faecalis in a pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

In vitro activity of teicoplanin compared with vancomycin against methicillin-resistant Staphylococcus aureus derived from cystic fibrosis sputum

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

In vitro killing activities of antibiotics at clinically achievable concentrations in cerebrospinal fluid against penicillin-resistant Streptococcus pneumoniae isolated from children with meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

In vitro evaluation of high-level, gentamicin-resistant enterococci isolated from bacteremic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Enterococcus faecium: in vitro activity of antimicrobial drugs, singly and combined, with and without defibrinated human blood, against multiple-antibiotic-resistant strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Coagulase-negative staphylococci: pathogens associated with medical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Update on clinical significance of coagulase-negative staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Epidemiology of infection in ICUs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Emergence of vancomycin resistance in coagulase-negative staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Peritonitis due to vancomycin-resistant Staphylococcus epidermidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Prevalence of antibiotic resistance among clinical isolates of methicillin-resistant staphylococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

In-vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Coagulase-negative staphylococci emerging during teicoplanin therapy and problems in the determination of their sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Coagulase-negative staphylococci emerging during teicoplanin therapy and the determination of their sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Emerging multiply resistant enterococci among clinical isolates. II. Validation of the etest to recognize glycopeptide-resistant strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Genetics and mechanisms of glycopeptide resistance in enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Hospital-acquired Infection with Vancomycin-resistant Enterococcus faecium Transmitted by Electronic Thermometers

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

High-level resistance to gentamicin in Streptococcus faecalis: risk factors and evidence for exogenous acquisition of infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Bacteremia due to vancomycin-dependent Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Bacteremia due to methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Therapy of staphylococcal infections with cefamandole or vancomycin alone or with a combination of cefamandole and tobramycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Vancomycin therapy of oxacillin-resistant Staphylococcus aureus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Serum Vancomycin Concentrations: Reappraisal of Their Clinical Value

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Monitoring serum vancomycin levels: climbing the mountain because it is there?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Vancomycin therapeutic drug monitoring: is it necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Once daily antibiotic regimen in paediatric oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Right-sided endocarditis caused by Staphylococcus aureus in drug abusers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Treatment of bone and soft tissue infections with teicoplanin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Efficacy of teicoplanin for enterococcal infections: 63 cases and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Teicoplanin in the treatment of gram-positive-bacterial endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Dosage recommendations for teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

The comparative efficacy and safety of teicoplanin and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Making sense of meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Meta-analyses of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Thrombocytopenia due to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

The nephrotoxicity of antimicrobial agents (second of three parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Vancomycin toxicity: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome".

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Vancomycin and the red-man syndrome: pharmacodynamics of histamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Vancomycin-induced histamine release and "red man syndrome": comparison of 1- and 2-hour infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Influence of antihistamine pretreatment on vancomycin-induced red-man syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Red man syndrome: incidence, etiology, and prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Survival and therapy of burn patients at the threshold of the twenty-first century: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Pharmacokinetics of systemically administered antibiotics in patients with thermal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Altered vancomycin dose vs. serum concentration relationship in burn patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

Vancomycin pharmacokinetics in burn patients and intravenous drug abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.1997.9.5.311

21 January 2018

Identifiers

DOI

10.1179/JOC.1997.9.5.311

1 reference

6 October 2017

1 reference

PubMed ID

9373787